Butyrate activates GPR109A, eliciting anti-inflammatory effects, promoting fat oxidation, and improving insulin sensitivity, highlighting its potential as a target for obesity treatment [98]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.